NEW YORK (GenomeWeb) – Roche said today that it has received the CE mark for its Navify Mutation Profiler clinical software, which it launched today.

The software provides annotation, interpretation, and clinical reporting of next-generation sequencing tests for cancer. Along with it, Roche launched Navify Therapy Matcher, an optional clinical decision support app that helps clinicians link clinically actionable mutations to therapy options.